PolyActiva
PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants using its proprietary PREZIA™ polymeric prodrug platform, targeting glaucoma, diabetic macular edema, and rare retinal diseases through single-administration sustained drug delivery lasting up to 12 months.
- Company typePrivate
- Founded2010
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PolyActiva does
PolyActiva Pty Ltd is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, with a U.S. operations office in Fort Worth, Texas. The company develops biodegradable ocular implants using its proprietary PREZIA™ Sustained Drug Delivery Technology platform, a polymeric prodrug system that chemically attaches a drug to a carrier polymer to enable site-specific, controlled drug delivery to the eye for periods ranging from one week to twelve months. Its product portfolio targets ophthalmic diseases where poor patient compliance with daily eye drops or the burden of frequent intravitreal injections limits clinical outcomes. Lead asset PA5108 is a six-month sustained-release Latanoprost Acid intracameral implant for open-angle glaucoma and ocular hypertension, currently in Phase 2b trials in the U.S. (NCT06964191). PA5346 is a second-generation 12-month Latanoprost Acid implant in Phase I, PA5691 is a Dexamethasone intravitreal implant for Diabetic Macular Edema in pre-clinical development, and an undisclosed fourth program for inherited retinal diseases is being co-developed with RareSight Inc.
PolyActiva is pre-revenue: products are investigational and not approved by FDA, and the company's website carries an explicit disclaimer that products are not for sale in the U.S. The company has raised approximately AUD $50.7M to date, including a Series B of AUD $9.2M in February 2013, a AUD $1.5M CUREator Grant in May 2024, and a AUD $40M Series C in May 2025 co-led by the Australian National Reconstruction Fund and Brandon Capital. The Series C proceeds are allocated to Phase 2b and Phase 3 development of PA5108, broader pipeline expansion using the PREZIA platform, and U.S. commercial preparation.
The go-to-market model, once products are approved, is enterprise field sales to ophthalmologists and eye care professionals for in-office administration of the micro-implants. The intellectual property estate covers eight active patent families comprising more than 160 granted patents and 17 pending applications across major jurisdictions, with four families and 60 granted patents specifically protecting the glaucoma program. The company was founded in 2010 (some sources cite 2009) and operates with 11-50 employees under a leadership team that was substantially refreshed in mid-2025 to add U.S. biopharma commercial experience ahead of late-stage clinical development and U.S. market entry.
PolyActiva firmographics
Firmographics- Name
- PolyActiva
- Legal name
- PolyActiva Pty Ltd
- Website
- https://polyactiva.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants using its proprietary PREZIA™ polymeric prodrug platform, targeting glaucoma, diabetic macular edema, and rare retinal diseases through single-administration sustained drug delivery lasting up to 12 months.
- Ownership category
- akta.pro rank
PolyActiva industry classification
Industry- Product category
- Ocular Drug Delivery / Ophthalmic Pharmaceuticals
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Rare Ophthalmology Disorder Therapies (HLAIAIAK), Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
Keywords
Where PolyActiva is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
PolyActiva business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Ocular Drug Delivery Implants: PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants. Revenue will be generated from the sale of prescription drug products (PA5108, PA5346, PA5691) for ophthalmic diseases such as glaucoma and diabetic macular edema. Products are not yet approved or commercialized.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
PolyActiva product offering
Product offeringCore offering
PolyActiva develops and is preparing to commercialize a portfolio of biodegradable ocular micro-implants that deliver sustained, controlled doses of ophthalmic drugs directly into the eye for periods of 1 week to 12 months. The lead candidate, PA5108, is a 6-month Latanoprost Acid implant for open-angle glaucoma and ocular hypertension currently in Phase 2b trials, with a 12-month second-generation implant (PA5346) and a Dexamethasone intravitreal implant (PA5691) in earlier development.
Product overview
PolyActiva is a clinical-stage biopharmaceutical company developing a portfolio of biodegradable ocular implants based on its proprietary PREZIA™ sustained drug delivery technology platform. The platform uses polymeric prodrug conjugates to enable site-specific, precise, and controlled drug delivery to the eye. The lead product, PA5108, is a 6-month Latanoprost Acid implant for glaucoma currently in Phase IIb trials. PA5346 is a second-generation 12-month implant in Phase I. PA5691 is a Dexamethasone implant for Diabetic Macular Edema in pre-clinical development. A fourth undisclosed program for inherited retinal diseases is being developed in partnership with RareSight Inc.
Differentiator
Problem solved
Functional benefit
Brands
- PREZIA™: Proprietary sustained drug delivery technology platform for precise and controlled drug delivery to the eye, enabling biodegradable ocular implants
Products and services
- PA5108 Latanoprost Acid Ocular Micro-Implant 6-month sustained release intracameral ocular micro-implant delivering Latanoprost Acid directly into the eye for reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Administered in ophthalmologists' offices; fully biodegradable; no implant movement after administration. Phase 2 data showed 26–35% IOP reduction sustained over 48 weeks, with 94% of patients not requiring additional drop therapy.
- PA5346 Latanoprost Acid Ocular Micro-Implant (12-month) Second-generation 12-month sustained release Latanoprost Acid ocular micro-implant for extended dosing in a single administration for glaucoma and ocular hypertension patients. Currently in Phase I clinical trial.
- PA5691 Dexamethasone Intravitreal Implant Micro ocular implant delivered intravitreally for controlled, sustained release of Dexamethasone for back-of-eye diseases such as Diabetic Macular Edema (DME). Currently in pre-clinical stage.
- PolyActiva Rare Pediatric Retinal Disease Program (with RareSight Inc.) Undisclosed sustained release implant for inherited retinal disease, co-developed with RareSight Inc. for rare pediatric retinal diseases using the PREZIA platform. Currently in pre-clinical development.
Quantifiable outcome
- 26-35% clinically meaningful IOP reduction over 48-week treatment period
- +3 more outcomes
Companies that use PolyActiva
Customer profileSegments2 records
Ideal customer profiles2 records
PolyActiva technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PolyActiva partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RareSight Inc.coreStrategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases using PolyActiva's PREZIA™ platform. The joint effort aims to create long-acting, intravitreally administered treatments for inherited retinal disorders that currently lack approved drug options. Partnership leverages PolyActiva's proprietary platform to offer first-of-its-kind, NCE-eligible pro-drug candidates.
Scale indicators6 records
Recent moves2 records
Expansion highlights6 records
PolyActiva competitors and assessment
Company assessmentDirect peers
- Alimera Sciences: Markets ILUVIEN, a sustained-release intravitreal fluocinolone acetonide implant for DME, directly comparable to PolyActiva's PA5691 (Dexamethasone implant for DME).
- Glaukos Corporation: Glaukos developed iDose TR, an intracameral sustained-release bimatoprost implant for glaucoma, the most direct competitor to PolyActiva's PA5108 in the sustained-release glaucoma space.
- Ocular Therapeutix: Develops sustained-release ocular implants including DEXTENZA (dexamethasone intracanalicular insert) and OTX-TIC (travoprost intracameral implant), directly comparable to PolyActiva's PREZIA platform in mechanism and ophthalmic indications.
- EyePoint Pharmaceuticals: Specializes in sustained-release ocular drug delivery using bioerodible Durasert and Verisome technologies, competing directly with PolyActiva in back-of-eye and anterior segment indications including DME.
Broad incumbents
- Bausch + Lomb: Major ophthalmic pharmaceutical incumbent that markets XIPERE (suprachoroidal triamcinolone) and a broad portfolio competing with PolyActiva across multiple ocular indications.
- AbbVie (Allergan Aesthetics/Eye Care): Markets DURYSTA, the first FDA-approved sustained-release bimatoprost implant for glaucoma. As a global pharmaceutical incumbent, it competes with PolyActiva across ophthalmology with broader resources and commercial reach.
- Santen Pharmaceutical: Japanese specialty ophthalmology company and prior employer of PolyActiva's CEO; competes broadly in glaucoma therapeutics and is a likely strategic acquirer of companies like PolyActiva.
- Nicox: European ophthalmology specialty company developing novel therapeutics for glaucoma and other ocular conditions, including sustained-release approaches, with overlapping investor and personnel networks with PolyActiva.
Emerging players
- Kodiak Sciences: Clinical-stage biopharmaceutical company developing novel therapeutics for retinal diseases, partially overlapping with PolyActiva's PA5691 and rare retinal disease programs.
- Kala Bio: Clinical-stage ophthalmic company with proprietary mucus-penetrating particle technology, focused on rare ocular conditions including rare orphan retinal indications that overlap with PolyActiva's rare disease strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PolyActiva social profiles
Digital presencePolyActiva financial estimates
Financial estimateRevenue estimate
Valuation estimate
PolyActiva leadership team
Management profileNumber of profiles
Profiles13 records
PolyActiva funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PolyActiva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PolyActiva
What does PolyActiva do?
PolyActiva develops and is preparing to commercialize a portfolio of biodegradable ocular micro-implants that deliver sustained, controlled doses of ophthalmic drugs directly into the eye for periods of 1 week to 12 months. The lead candidate, PA5108, is a 6-month Latanoprost Acid implant for open-angle glaucoma and ocular hypertension currently in Phase 2b trials, with a 12-month second-generation implant (PA5346) and a Dexamethasone intravitreal implant (PA5691) in earlier development.
Is PolyActiva a public or private company?
PolyActiva is a private company. It is classified as venture growth investor backed and is currently operating.
When was PolyActiva founded?
PolyActiva was founded in 2010. It employs 11 to 50 people.
Where is PolyActiva based?
PolyActiva is headquartered in Melbourne, Australia, in the Oceania region.
How does PolyActiva make money?
One revenue line is on record: ocular Drug Delivery Implants.
Who are PolyActiva's main competitors?
Direct peers on record are Alimera Sciences, Glaukos Corporation, Ocular Therapeutix and EyePoint Pharmaceuticals. Broad incumbents are Bausch + Lomb, AbbVie (Allergan Aesthetics/Eye Care), Santen Pharmaceutical and Nicox. Emerging players are Kodiak Sciences and Kala Bio.
Does PolyActiva have an API?
No public API is recorded for PolyActiva.
What industry is PolyActiva in?
PolyActiva's product category is Ocular Drug Delivery / Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3841.